IN the know

Strengthening rare-disease pharmacovigilance with curated real-world data

By Lucy Fulford-Smith, TMC

29 September 2025

IN the know

Employing advanced analytics and artificial intelligence in rare-disease pharmacovigilance

By Lucy Fulford-Smith, TMC

22 September 2025

IN the know

The limits of traditional pharmacovigilance in rare diseases

By Lucy Fulford-Smith, TMC

15 September 2025

IN the know

The future of life sciences is out there

By Michael Wilbur, MW Advocacy Solutions

1 September 2025

IN the know

No true north: The disbanding of ACHDNC and its impact on rare disease innovation

By Amy Gaviglio, Connetics Consulting

18 August 2025

IN the know

When policy fails people: Reimagining medicines access for rare conditions

By Henry Burkitt, Oxygen Strategy

11 August 2025

IN the know

The problem with the zebra: Why global awareness campaigns must be rooted in local leadership

By Michael Wilbur, MW Advocacy Solutions

21 July 2025

IN the know

Houston we have a problem: NASA-inspired strategies for rare disease

By Michael Wilbur, MW Advocacy Solutions

30 June 2025

IN the know

Capturing real-world data: “the right data, at the right time, in the right way”

By Michelle Conway

7 June 2025

IN the know

The future of rare disease policy in England: what the DHSC takeover of NHS England means for patients and progress

By Henry Burkitt, Oxygen Strategy

7 June 2025